POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells
[Display omitted] PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of inv...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmaceutics and biopharmaceutics 2018-10, Vol.131, p.162-169 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 169 |
|---|---|
| container_issue | |
| container_start_page | 162 |
| container_title | European journal of pharmaceutics and biopharmaceutics |
| container_volume | 131 |
| creator | de Melo-Diogo, Duarte Costa, Elisabete C. Alves, Cátia G. Lima-Sousa, Rita Ferreira, Paula Louro, Ricardo O. Correia, Ilídio J. |
| description | [Display omitted]
PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent. |
| doi_str_mv | 10.1016/j.ejpb.2018.08.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2092536360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641118306064</els_id><sourcerecordid>2092536360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c298t-f2b4ef9c8c9f07ae8c5348273c2b41f8a14d73a549db792dd2dd3c03a72b69603</originalsourceid><addsrcrecordid>eNp9kEtv2zAQhImgQeKk_QM9FDz2Inf5kEQCvRRBHgUCpIfkzFDkqqZhiSopB_a_Dx2nPRYYYA87M9j9CPnMYMmANd_WS1xP3ZIDU0soAnVCFky1ohJSsg9kAVroqpGMnZOLnNcAINtanZFzAUxIpuoFef71sNtv7Iye_k52WuGINO6CRzraMQ5lkYLdZNrHRF0cujDaOcSRuhUOsZpWcY7zCktyT2NPu4Q2z9TZ0WHx42aTP5LTvhTgp_d5SZ5urh-v7qr7h9ufVz_uK8e1mquedxJ77ZTTPbQWlauFVLwVrixYryyTvhW2ltp3rebeFwkHwra8a3QD4pJ8PfZOKf7ZYp7NEPLhAjti3GbDQfNaNOLNyo9Wl2LOCXszpTDYtDcMzIGsWZsDWXMga6AIVAl9ee_fdgP6f5G_KIvh-9GA5cuXgMlkF7CA8CGhm42P4X_9r82ni6U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2092536360</pqid></control><display><type>article</type><title>POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>de Melo-Diogo, Duarte ; Costa, Elisabete C. ; Alves, Cátia G. ; Lima-Sousa, Rita ; Ferreira, Paula ; Louro, Ricardo O. ; Correia, Ilídio J.</creator><creatorcontrib>de Melo-Diogo, Duarte ; Costa, Elisabete C. ; Alves, Cátia G. ; Lima-Sousa, Rita ; Ferreira, Paula ; Louro, Ricardo O. ; Correia, Ilídio J.</creatorcontrib><description>[Display omitted]
PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2018.08.008</identifier><identifier>PMID: 30134185</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>alpha-Tocopherol - administration & dosage ; alpha-Tocopherol - chemistry ; Antibiotics, Antineoplastic - administration & dosage ; Antibiotics, Antineoplastic - chemistry ; Antineoplastic Agents - therapeutic use ; Antioxidants - administration & dosage ; Antioxidants - chemistry ; Breast Neoplasms - drug therapy ; Breast Neoplasms - therapy ; Cancer treatment ; Co-delivery ; Combined Modality Therapy ; Doxorubicin - administration & dosage ; Doxorubicin - chemistry ; Drug Delivery Systems ; Drug Screening Assays, Antitumor ; Drug Synergism ; Female ; Graphene oxide ; Graphite - chemistry ; Humans ; MCF-7 Cells ; Nanostructures - chemistry ; Phototherapy - methods ; Photothermal therapy ; POxylation</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2018-10, Vol.131, p.162-169</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c298t-f2b4ef9c8c9f07ae8c5348273c2b41f8a14d73a549db792dd2dd3c03a72b69603</citedby><cites>FETCH-LOGICAL-c298t-f2b4ef9c8c9f07ae8c5348273c2b41f8a14d73a549db792dd2dd3c03a72b69603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0939641118306064$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30134185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Melo-Diogo, Duarte</creatorcontrib><creatorcontrib>Costa, Elisabete C.</creatorcontrib><creatorcontrib>Alves, Cátia G.</creatorcontrib><creatorcontrib>Lima-Sousa, Rita</creatorcontrib><creatorcontrib>Ferreira, Paula</creatorcontrib><creatorcontrib>Louro, Ricardo O.</creatorcontrib><creatorcontrib>Correia, Ilídio J.</creatorcontrib><title>POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted]
PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent.</description><subject>alpha-Tocopherol - administration & dosage</subject><subject>alpha-Tocopherol - chemistry</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antibiotics, Antineoplastic - chemistry</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antioxidants - administration & dosage</subject><subject>Antioxidants - chemistry</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer treatment</subject><subject>Co-delivery</subject><subject>Combined Modality Therapy</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Drug Synergism</subject><subject>Female</subject><subject>Graphene oxide</subject><subject>Graphite - chemistry</subject><subject>Humans</subject><subject>MCF-7 Cells</subject><subject>Nanostructures - chemistry</subject><subject>Phototherapy - methods</subject><subject>Photothermal therapy</subject><subject>POxylation</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtv2zAQhImgQeKk_QM9FDz2Inf5kEQCvRRBHgUCpIfkzFDkqqZhiSopB_a_Dx2nPRYYYA87M9j9CPnMYMmANd_WS1xP3ZIDU0soAnVCFky1ohJSsg9kAVroqpGMnZOLnNcAINtanZFzAUxIpuoFef71sNtv7Iye_k52WuGINO6CRzraMQ5lkYLdZNrHRF0cujDaOcSRuhUOsZpWcY7zCktyT2NPu4Q2z9TZ0WHx42aTP5LTvhTgp_d5SZ5urh-v7qr7h9ufVz_uK8e1mquedxJ77ZTTPbQWlauFVLwVrixYryyTvhW2ltp3rebeFwkHwra8a3QD4pJ8PfZOKf7ZYp7NEPLhAjti3GbDQfNaNOLNyo9Wl2LOCXszpTDYtDcMzIGsWZsDWXMga6AIVAl9ee_fdgP6f5G_KIvh-9GA5cuXgMlkF7CA8CGhm42P4X_9r82ni6U</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>de Melo-Diogo, Duarte</creator><creator>Costa, Elisabete C.</creator><creator>Alves, Cátia G.</creator><creator>Lima-Sousa, Rita</creator><creator>Ferreira, Paula</creator><creator>Louro, Ricardo O.</creator><creator>Correia, Ilídio J.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181001</creationdate><title>POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells</title><author>de Melo-Diogo, Duarte ; Costa, Elisabete C. ; Alves, Cátia G. ; Lima-Sousa, Rita ; Ferreira, Paula ; Louro, Ricardo O. ; Correia, Ilídio J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c298t-f2b4ef9c8c9f07ae8c5348273c2b41f8a14d73a549db792dd2dd3c03a72b69603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>alpha-Tocopherol - administration & dosage</topic><topic>alpha-Tocopherol - chemistry</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antibiotics, Antineoplastic - chemistry</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antioxidants - administration & dosage</topic><topic>Antioxidants - chemistry</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer treatment</topic><topic>Co-delivery</topic><topic>Combined Modality Therapy</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Drug Synergism</topic><topic>Female</topic><topic>Graphene oxide</topic><topic>Graphite - chemistry</topic><topic>Humans</topic><topic>MCF-7 Cells</topic><topic>Nanostructures - chemistry</topic><topic>Phototherapy - methods</topic><topic>Photothermal therapy</topic><topic>POxylation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>de Melo-Diogo, Duarte</creatorcontrib><creatorcontrib>Costa, Elisabete C.</creatorcontrib><creatorcontrib>Alves, Cátia G.</creatorcontrib><creatorcontrib>Lima-Sousa, Rita</creatorcontrib><creatorcontrib>Ferreira, Paula</creatorcontrib><creatorcontrib>Louro, Ricardo O.</creatorcontrib><creatorcontrib>Correia, Ilídio J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Melo-Diogo, Duarte</au><au>Costa, Elisabete C.</au><au>Alves, Cátia G.</au><au>Lima-Sousa, Rita</au><au>Ferreira, Paula</au><au>Louro, Ricardo O.</au><au>Correia, Ilídio J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2018-10-01</date><risdate>2018</risdate><volume>131</volume><spage>162</spage><epage>169</epage><pages>162-169</pages><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted]
PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30134185</pmid><doi>10.1016/j.ejpb.2018.08.008</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-6411 |
| ispartof | European journal of pharmaceutics and biopharmaceutics, 2018-10, Vol.131, p.162-169 |
| issn | 0939-6411 1873-3441 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2092536360 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | alpha-Tocopherol - administration & dosage alpha-Tocopherol - chemistry Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - chemistry Antineoplastic Agents - therapeutic use Antioxidants - administration & dosage Antioxidants - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - therapy Cancer treatment Co-delivery Combined Modality Therapy Doxorubicin - administration & dosage Doxorubicin - chemistry Drug Delivery Systems Drug Screening Assays, Antitumor Drug Synergism Female Graphene oxide Graphite - chemistry Humans MCF-7 Cells Nanostructures - chemistry Phototherapy - methods Photothermal therapy POxylation |
| title | POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T03%3A02%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=POxylated%20graphene%20oxide%20nanomaterials%20for%20combination%20chemo-phototherapy%20of%20breast%20cancer%20cells&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=de%20Melo-Diogo,%20Duarte&rft.date=2018-10-01&rft.volume=131&rft.spage=162&rft.epage=169&rft.pages=162-169&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2018.08.008&rft_dat=%3Cproquest_cross%3E2092536360%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2092536360&rft_id=info:pmid/30134185&rft_els_id=S0939641118306064&rfr_iscdi=true |